Rep. Thomas H. Kean, Jr. Buys Becton, Dickinson and Company (NYSE:BDX) Stock

Representative Thomas H. Kean, Jr. (R-New Jersey) recently bought shares of Becton, Dickinson and Company NYSE: BDX. In a filing disclosed on June 17th, the Representative disclosed that they had bought between $1,001 and $15,000 in Becton, Dickinson and Company stock on May 13th. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 6/26/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.
• Purchased $1,001 - $15,000 in shares of Danaher NYSE: DHR on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of AON NYSE: AON on 5/27/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 5/8/2025.
• Sold $1,001 - $15,000 in shares of Crown NYSE: CCK on 5/8/2025.
• Purchased $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 5/5/2025.
• Sold $1,001 - $15,000 in shares of Franklin Resources NYSE: BEN on 4/28/2025.
• Purchased $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 4/24/2025.

Becton, Dickinson and Company Trading Up 0.1%

Shares of NYSE BDX traded up $0.21 during mid-day trading on Friday, reaching $183.84. The company had a trading volume of 146,374 shares, compared to its average volume of 2,629,662. The business's 50-day moving average is $174.10 and its 200-day moving average is $203.07. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The stock has a market cap of $52.69 billion, a price-to-earnings ratio of 35.13, a price-to-earnings-growth ratio of 1.38 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.17 earnings per share. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 79.39%.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently modified their holdings of the company. Bank of Jackson Hole Trust purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $25,000. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $27,000. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Finally, REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Morgan Stanley cut their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a report on Friday, May 2nd. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Barclays dropped their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $219.22.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.